Skip to content
RADIOLABELED ANTIBODIES / TUMOR TARGETING

CD20 · CD37 · CD45 · PSMA · 2026

Tumor radioimmunotherapy has an established clinical lineage, but each new isotope must prove its own place in care.

Antibody-based tumor irradiation is not interchangeable with small-molecule radioligand therapy. Mature lymphoma studies, a randomized AML transplant strategy and new alpha-emitting platforms illuminate very different adoption pathways.

5 selected clinical studiesPrimary study and regulator sourcesReviewed 2026-11-22
SIERRA / PRIMARY RANDOMIZED ENDPOINT17.1%Durable complete remission versus 0% with conventional care, intention-to-treat AML population

Primary study ↗

01 / TARGET MATTERSA CD20 lymphoma consolidation regimen does not validate an anti-PSMA alpha-emitter.
02 / CARE PATHWAYRadiation handling, marrow reserve and hematology workflows shape access.
03 / EVIDENCE GRADERandomized endpoints must be separated from early response and dose-finding signals.

Tumor radioimmunotherapy has an established clinical lineage, but each new isotope must prove its own place in care.

Tumor radioimmunotherapy refers here to therapeutic radiation delivered through a monoclonal antibody or an antibody-derived construct that recognizes a tumor-associated antigen. It includes well-established CD20-directed radionuclide conjugates, investigational CD37 antibodies and anti-CD45 conditioning agents, and newer antibodies carrying alpha emitters. It does not automatically include every radioligand product that binds PSMA or somatostatin receptors, because many of those treatments use small molecules or peptides rather than antibodies.

The distinction is commercially consequential. Antibodies differ in molecular size, circulation time, target penetration, off-target organ exposure, clearance and compatibility with an isotope half-life. The relevant buyer may be a lymphoma center, an allogeneic-transplant service, a nuclear-medicine department or an integrated radiopharmacy. Each setting has a different clinical workflow and patient selection funnel. A single market number cannot substitute for those practical differences.

Five source-linked studies span historical consolidation, direct treatment-strategy comparison and newer precommercial programs. Interpreting them together is useful for understanding technological direction, but their outcome percentages are not suitable for a pooled efficacy ranking.

RESEARCH INTERPRETATION

Clinical analysis of antibody-radionuclide therapies across lymphoma, leukemia and prostate cancer, separating randomized treatment evidence from exploratory dose-finding.

How the selected clinical programs differ

The study table compares populations, interventions and questions. No cross-trial response ranking is implied. A registry record documents a planned or conducted study; efficacy claims below refer only to published primary results.

5 studies
Study designs and populations—not a cross-trial efficacy ranking
Clinical study and official registryTherapy / technologyPopulationDesign and comparison
SIERRAI-131 apamistamab, anti-CD45Patients 55 years or older with active relapsed/refractory acute myeloid leukemiaRandomized phase III: antibody-led transplant strategy versus conventional care
LYMRIT-37-01 / PARADIGMELu-177 lilotomab satetraxetan, anti-CD37Rituximab-refractory follicular B-cell lymphoma after prior lines of therapySingle-arm/regimen evaluation; phase I/II and later phase II analyses
ZAR2007Y-90 ibritumomab tiuxetan, anti-CD20Previously untreated follicular lymphoma responding to R-CHOP inductionRandomized phase II: single radioimmunotherapy consolidation versus rituximab maintenance
225Ac-J591 phase IAc-225–J591 antibody, targeting PSMAPretreated metastatic castration-resistant prostate cancerEarly-phase dose escalation and tolerability assessment
LUTEONLu-177 girentuximab, anti-CAIX; imaging selectionCAIX-expressing advanced or recurrent clear-cell renal cancerBiomarker-enriched prospective treatment program; phase III registry/protocol

Study stage and current recruitment status can change; primary publications and registry snapshots should be checked before posting a live status.

SIERRA: I-131 apamistamab, anti-CD45

The published intention-to-treat durable complete remission rate was 17.1% versus 0% with conventional care; durable remission required at least 180 days.

CD45 is displayed across the hematopoietic compartment rather than uniquely on malignant blasts. That makes the program principally a pretransplant radiation-and-conditioning strategy. The commercial unit is not merely a vial of radiolabeled antibody: transplantation availability, protective radiation procedures, marrow exposure and center credentials matter.

The endpoint is protocol-specific and depends on a treatment pathway that includes allogeneic transplantation. The result does not establish the benefit of the antibody alone or efficacy in solid tumors.

Study record: NCT02665065 · Original clinical source: read publication or official study detail

LYMRIT-37-01 / PARADIGME: Lu-177 lilotomab satetraxetan, anti-CD37

Published phase II analysis reported objective responses of 38.9% in one regimen group and 32.1% in another; these were not randomized comparisons with standard of care.

CD37 offers a B-cell target different from CD20. In a disease where treatment sequencing now includes multiple antibody, cellular and small-molecule options, response durability and marrow recovery become more informative than a response percentage alone. Different administered activities and marrow-dosing assumptions influence whether centers can reproduce an investigational regimen.

The dosing-cohort response rates should not be interpreted as a definitive superiority comparison. Thrombocytopenia and prior marrow treatment burden constrain eligibility; a study being published is not proof of regulatory approval.

Study record: NCT01796171 · Original clinical source: read publication or official study detail

ZAR2007: Y-90 ibritumomab tiuxetan, anti-CD20

The investigators tested a finite post-induction consolidation against two years of anti-CD20 maintenance and published long-term follow-up.

This study illustrates an older but unusually clear purchasing question: can one scheduled radiolabeled-antibody course replace or compete with a prolonged maintenance plan? Logistics, facility access and the patient’s preference for treatment frequency may influence uptake separately from efficacy or reimbursement. The comparator is relevant because both pathways were actually studied after R-CHOP in the same clinical context.

Induction, eligibility and protocol timing are essential to interpretation. No inference about contemporary bispecific antibodies or CAR-T sequencing follows directly from this historical regimen comparison.

Study record: NCT00662948 · Original clinical source: read publication or official study detail

225Ac-J591 phase I: Ac-225–J591 antibody, targeting PSMA

Published first-in-human research evaluates safety and dose development for an alpha-emitting antibody, not randomized survival benefit.

The antibody carrier has a different clearance and tissue-distribution profile from small-molecule PSMA radioligands. An alpha emitter can deposit high-energy radiation over a short path length, but that physical property does not predict clinical benefit on its own. Dosing choices must account for marrow exposure, prior therapies and radiation protection, while supply planning depends on reliable isotope sourcing.

PSA reductions or exploratory imaging findings in a dose-escalation cohort do not demonstrate that J591 outperforms a licensed PSMA radioligand. The appropriate next question is whether the regimen delivers acceptable tumor exposure without unacceptable organ dose.

Study record: NCT03276572 · Original clinical source: read publication or official study detail

LUTEON: Lu-177 girentuximab, anti-CAIX; imaging selection

A prospective program linking CAIX imaging and treatment has been described; outcomes should not be reported before a primary readout.

The development proposition is that a companion diagnostic can identify tumors that are actually reachable by a therapeutic antibody. A coherent service line requires diagnostic tracer supply, reading standards, therapeutic activity planning and longitudinal radiation monitoring. It would also need evidence that imaging selection improves real treatment decisions rather than simply describing target expression.

Until comparative results emerge, neither activity nor survival benefit can be presumed. The imaging and treatment agents have different radiochemistry, and one scan cannot replace a full organ-dosimetry assessment.

Study record: NCT07197580 · Original clinical source: read publication or official study detail

SIERRA: durable complete remission lasting 180 days

This visualization is deliberately confined to one study. Comparing values from different cancers, protocols or treatment lines on a single graph would create a false impression of treatment equivalence.

WITHIN-STUDY DATA

SIERRA: durable complete remission lasting 180 days

Percent of randomized intention-to-treat patients
I-131 apamistamab strategy17.1%
Conventional-care strategy0%

Randomized SIERRA trial, NCT02665065. The study evaluates a transplant strategy, not antibody infusion against placebo.

The lymphoma precedent and its limits

Y-90 ibritumomab demonstrates that radioimmunotherapy can have a specific treatment role rather than only a laboratory rationale. The FIT-era and ZAR2007 studies concern CD20-expressing lymphoma after a defined induction or as an earlier treatment strategy. Their lessons remain relevant to workflow and product handling, but clinical practice has moved on: anti-CD20 maintenance, immunomodulatory combinations, bispecific antibodies and CAR-T can change both the addressable population and the comparator expected by clinicians.

A modern study therefore needs a credible clinical control and a population that reflects current treatment exposure. A regimen that performs well in a historical, less heavily pretreated population may face a harder test after multiple targeted therapies. Sales forecasts that simply translate an older response rate into patients treated overlook both the eligible line of therapy and center capacity.

Target selection, isotope matching and dosimetry

The therapeutic logic is a chain: choose an antigen, attach a stable radiometal or radiohalogen, confirm sufficient tumor delivery, constrain absorbed dose to marrow and other organs, then establish a patient pathway. Failure at any link can compromise the treatment. Tumor heterogeneity makes antigen-positive pathology necessary but not always sufficient; a tissue specimen does not map every metastasis.

Isotope half-life must fit the antibody pharmacokinetics. Beta emitters can deposit energy over a longer range, whereas alpha emitters have high linear energy transfer over much shorter tracks. This difference creates hypotheses about tumor microdistribution and toxicity, not an automatic efficacy ranking. Practical feasibility also depends on batch release, radiochemical stability, transport time and institution-specific handling rules.

Clinical infrastructure becomes the commercial filter

Radioimmunotherapy requires coordination among medical oncology or hematology, nuclear medicine, medical physics, radiopharmacy and infusion services. Scheduling can depend on radiotracer availability, radiation-safety staffing, isotope calibration and patient-specific hematologic suitability. A manufacturer’s distribution promise is not equivalent to the number of centers capable of delivering its regimen.

For AML conditioning, transplant access and donor readiness create additional bottlenecks. For an outpatient antibody-radionuclide program, same-day handling and patient follow-up may dominate. A payer may evaluate hospitalization and entire treatment episodes, not simply the acquisition price of a radiopharmaceutical dose.

What would alter competitive positioning

The next meaningful results differ by segment. In lymphoma, randomized comparisons against current maintenance or advanced-line treatment would resolve a modern therapeutic question. For anti-PSMA antibodies, optimized dosing and controlled efficacy data must complement early biomarker responses. For CAIX-directed therapy, selection thresholds, imaging reproducibility and meaningful clinical endpoints will determine whether the diagnostic-treatment pair changes practice.

Durable response, survival, adverse marrow events, hospitalization burden and treatment completion should be reported with their own denominators. Early responders should not be mixed with randomized remission rates in a commercial benchmark. Investor and procurement assessments should distinguish licensed products, investigational medicines and enabling diagnostics.

Marrow exposure and eligibility are strategic constraints

Blood cancers are naturally attractive for antibody-radionuclide development because some targets are accessible to circulating antibodies and because hematopoietic malignancies can be radiation sensitive. But access to the target is inseparable from exposure of healthy marrow. A protocol may require minimum platelet counts, limited marrow involvement, a defined number of earlier regimens or an available stem-cell rescue strategy. These restrictions are part of the market definition, not mere trial administration. A forecast that counts every relapsed lymphoma patient while ignoring marrow reserve may materially overstate use.

The SIERRA and CD37 programs illustrate two different marrow-risk propositions. One deliberately couples targeted irradiation to subsequent stem-cell transplantation, making marrow ablation part of an integrated plan. The other is evaluated as a radiolabeled antibody treatment for lymphoma, where hematologic recovery influences dose and retreatment feasibility. The same isotope activity cannot be assumed safe or useful across these contexts. Quality teams must separately validate antibody integrity, radiolabel attachment and administered-activity measurement.

What constitutes a competitive trial in 2026?

A registrationally persuasive study should define a current comparator, a reproducible eligibility screen and a patient-important endpoint. Progression-free survival, event-free survival, durable remission and overall survival are not interchangeable. Where transplantation, induction chemotherapy or a diagnostic-imaging step accompanies the radionuclide, the comparison evaluates a strategy that includes those components. Publications should report how many enrolled patients actually received radiotherapy, completed treatment and reached later steps of the pathway.

For a new solid-tumor antibody, early escalation may appropriately emphasize safety, organ dose and a feasible treatment activity. Yet investors should avoid treating exploratory PSA falls, tumor shrinkage and biomarker uptake as three independent demonstrations of benefit. Later controlled research needs to determine whether the regimen improves meaningful outcomes against care that patients would otherwise receive. The existence of historical lymphoma approvals cannot shorten this evidentiary progression for a different antibody and isotope.

Supply-chain questions that belong in clinical diligence

The isotope supplier, labeling process, release assay and treatment site are interdependent. Short production and delivery windows can dictate center locations and scheduled patient slots; a failed batch can mean a clinically significant delay. Radiopharmacy production should quantify labeling yield, radionuclidic purity, stability at end of shelf life and methods for handling deviations. These are measurable questions for procurement and regulatory diligence, unlike broad claims that radioligands are universally scalable.

Diagnostic confirmation may also have its own supply chain. If trial enrollment depends on PET uptake by a labeled antibody, sponsors must ensure radiotracer availability, scanner scheduling and image-reading consistency before a therapeutic slot is booked. The commercial bottleneck can move between the diagnostic and treatment stages. Therefore a realistic opportunity assessment should model patient screening failures, center-level scheduling capacity and the proportion of prescribed doses actually administered.

Where clinical findings translate into purchase and adoption decisions

The most useful segmentation begins with indication and intent: lymphoma consolidation, refractory lymphoma salvage, AML transplant conditioning, and antibody-directed solid-tumor treatment. Segment next by antigen, radionuclide, patient selection, center readiness and whether the approach is a standalone treatment or part of a complex procedure. Product revenue cannot be inferred from trial response rates or announced trial counts.

The near-term bottlenecks are predictable from the clinical studies: radioisotope availability, therapy-specific dosimetry, certified handling sites, hematologic toxicity management and competition with treatments that do not require radiopharmacy. An antibody radionuclide may be clinically attractive yet commercially narrow if only a handful of transplant or nuclear-medicine centers can deliver it.

A credible forecast needs disease-specific eligible patients, treatment-line restrictions, radiopharmacy throughput, failure-to-treat rates and real reimbursement. Those inputs are not established by the five publications alone; no unsupported dollar estimate is supplied here.

What the current clinical results support

Tumor radioimmunotherapy is best evaluated as several distinct treatment businesses connected by an antibody-radiation platform. Randomized SIERRA data and older CD20 consolidation trials demonstrate that carefully selected settings can yield meaningful clinical endpoints, while CD37, PSMA and CAIX programs still face different evidence, toxicology and implementation tests.

Study records and original results

  1. SIERRA — NCT02665065 · original clinical source.
  2. LYMRIT-37-01 / PARADIGME — NCT01796171 · original clinical source.
  3. ZAR2007 — NCT00662948 · original clinical source.
  4. 225Ac-J591 phase I — NCT03276572 · original clinical source.
  5. LUTEON — NCT07197580 · original clinical source.

ClinicalTrials.gov public study records and primary publications were checked through web-accessible pages. Direct raw API v2 study JSON was not obtained. Study statuses and results may change after 2026-11-22.